The ATLANTA First in Man Study of the Catania Stent

Assessment of The Latest Non-Thrombogenic Angioplasty Stent (ATLANTA): Prospective, First in Man, Non-Randomized, Single Center for Patients With Documented Myocardial Ischemia Undergoing PCI

To evaluate the short-term and mid-term safety and efficacy of the Catania coronary stent for the treatment of up to two de novo lesions in native coronary arteries.

This is a prospective, non-randomized, first-in-man single center study. The study requires a 55 patients with documented myocardial ischemia undergoing PCI.

Inclusion Criteria:

• Lesion length ≤ 20 mm
• Vessel size ≥ 2.5 ≤ 3.5 mm

Exclusion Criteria:

• Life expectancy < 1 year
• Left ventricular ejection fraction (LVEF) <30%
• Anti-thrombotic drug intolerance